KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Total Liabilities (2016 - 2025)

TherapeuticsMD's Total Liabilities history spans 16 years, with the latest figure at $10.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 5.87% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $10.8 million, down 5.87%, while the annual FY2025 figure was $10.8 million, 5.87% down from the prior year.
  • Total Liabilities reached $10.8 million in Q4 2025 per TXMD's latest filing, down from $11.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $274.0 million in Q1 2022 to a low of $10.8 million in Q4 2025.
  • Average Total Liabilities over 5 years is $95.2 million, with a median of $22.5 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: rose 10.12% in 2022, then tumbled 89.93% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $263.1 million in 2021, then crashed by 78.98% to $55.3 million in 2022, then tumbled by 74.65% to $14.0 million in 2023, then fell by 18.33% to $11.5 million in 2024, then decreased by 5.87% to $10.8 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Total Liabilities are $10.8 million (Q4 2025), $11.2 million (Q3 2025), and $11.2 million (Q2 2025).